Corvas shifts opportunistically

Corvas shifts opportunistically Corvas International Inc. , long thought of as a cardiovascular company with a small inflammatory program, has been shifting the weight of its research and is now devoting about 40 percent of its resources to the latter. The change is a result of the discovery last year of neutrophil inhibitory factor (NIF), a protein that acts as an antagonist to the CD11/CD18 integrin receptor responsible for neutrophil activation, CVAS President and CEO David Kabakoff said at a meeting with BioCentury last week.

A year ago, 80-85 percent of CVAS's resources were devoted to anti-thrombotics, and two years ago the figure was 95 percent, Kabakoff said...